European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?
- DOI
- 10.1016/j.ejmg.2022.104575
- Published
- 2022-10
- Container
- European Journal of Medical Genetics
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejmg.2022.104575,
title = {European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?},
author = {Sophie Dupuis-Girod and Claire L. Shovlin and Anette D. Kjeldsen and Hans-Jurgen Mager and Carlo Sabba and Freya Droege and Anne-Emmanuelle Fargeton and Annette D. Fialla and Silvia Gandolfi and Ruben Hermann and Gennaro M. Lenato and Guido Manfredi and Marco C. Post and Catherine Rennie and Patrizia Suppressa and Ulrich Sure and Claudia Crocione and Ria Blom and Luisa Maria Botella and Fernando Brocca and Caroline Coxall and Karen T. Druckman and Didier Erasme and Paolo Federici and Christina Grabowski and Mildred Lundgren and Tone Søderman and Dara Woods and Elisabetta Buscarini},
year = {2022},
journal = {European Journal of Medical Genetics},
doi = {10.1016/j.ejmg.2022.104575},
url = {https://doi.org/10.1016/j.ejmg.2022.104575}
}RIS
TY - JOUR TI - European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)? AU - Sophie Dupuis-Girod AU - Claire L. Shovlin AU - Anette D. Kjeldsen AU - Hans-Jurgen Mager AU - Carlo Sabba AU - Freya Droege AU - Anne-Emmanuelle Fargeton AU - Annette D. Fialla AU - Silvia Gandolfi AU - Ruben Hermann AU - Gennaro M. Lenato AU - Guido Manfredi AU - Marco C. Post AU - Catherine Rennie AU - Patrizia Suppressa AU - Ulrich Sure AU - Claudia Crocione AU - Ria Blom AU - Luisa Maria Botella AU - Fernando Brocca AU - Caroline Coxall AU - Karen T. Druckman AU - Didier Erasme AU - Paolo Federici AU - Christina Grabowski AU - Mildred Lundgren AU - Tone Søderman AU - Dara Woods AU - Elisabetta Buscarini PY - 2022 JO - European Journal of Medical Genetics DO - 10.1016/j.ejmg.2022.104575 UR - https://doi.org/10.1016/j.ejmg.2022.104575 ER -
APA
Dupuis-Girod, S., Shovlin, C. L., Kjeldsen, A. D., Mager, H., Sabba, C., Droege, F., Fargeton, A., Fialla, A. D., Gandolfi, S., Hermann, R., Lenato, G. M., Manfredi, G., Post, M. C., Rennie, C., Suppressa, P., Sure, U., Crocione, C., Blom, R., Botella, L. M., Brocca, F., Coxall, C., Druckman, K. T., Erasme, D., Federici, P., Grabowski, C., Lundgren, M., Søderman, T., Woods, D., & Buscarini, E. (2022). European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?. European Journal of Medical Genetics. https://doi.org/10.1016/j.ejmg.2022.104575
Source records
- crossref · retrieved 2026-09-25T06:11:29.108Z